Source

Human B7-H7, his Tag Is expressed from human 293 cells (HEK293). It contains AA Ile 23 - Asn 344 (Accession # Q9UM44-1).

Predicted N-terminus: Ile 23

Molecular Characterization

This protein carries a his tag at the C-terminus.

Endotoxin

Less than 0.01 EU/mg by the LAL method.

Purity

>95% as determined by SDS-PAGE.

Bioactivity

ELISA ；

BIACORE (With our Research Grade Biosimilar Antibody products);

Formulation

Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

No activity loss was observed after storage at:

4-8°C for 12 months in lyophilized state;

-70°C for 3 months under sterile conditions after reconstitution.

Background

B7-H7 (HHLA2) is a newly identified B7 family member that regulates human T-cell functions. B7-H7 was previously known as human endogenous retrovirus-H long terminal repeat associating 2 (HHLA2) with unidentified function. Recently, B7-H7 has been identified as a specific ligand for human CD28H. The B7-H7-CD28H pathway strongly promoted CD4+ T-cell proliferation and cytokine production via an AKT-dependent signaling cascade in the presence of TCR signaling, suggesting B7-H7 comprises a new co-stimulatory pathway. The first IgV domain of B7-H7, which presumably binds to a putative receptor, shows the highest homology to other B7 family members.

Reference

(1) Ni L., et al., 2017, Mol. Cancer. Ther. 16:1203-1211.

(2) Jung K., et al., 2013, Immune. Netw. 13:184-193.

(3) Janakiram M., et al., 2015, Clin. Cancer. Res. 21:2359-2366.